CD22-targeted immunotherapy for B-cell acute lymphoblastic leukemia progressing following CD19-targeted immunotherapy

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) after CD19-targeted immunotherapy has poor outcomes.
• CD22-targeted therapies represent potential alternatives, but clinical data in this specific patient population is limited.

Purpose of the Study:

• To evaluate the efficacy and safety of CD22-targeted therapies in patients with r/r B-ALL who progressed after prior CD19-directed treatment.
• To compare CD22 CAR-T cells and Inotuzumab Ozogamicin in this setting.

Main Methods:

• Retrospective analysis of 43 r/r B-ALL patients treated at two centers in China.
• Patients had previously received CD19-targeted therapy (blinatumomab, CD19 CAR-T cells, or both).
• Subsequent treatments included CD22 CAR-T cells or Inotuzumab Ozogamicin (InO).

Main Results:

• Overall CR/CRi rate was 54%, with 35.1% achieving MRD negativity.
• CD22 CAR-T cells and InO demonstrated similar remission rates and survival outcomes.
• High relapse rates (59.1% among CR/CRi patients) were observed, emphasizing the need for further optimization.

Conclusions:

• CD22-targeted therapies are a viable option for patients with r/r B-ALL progressing after CD19-directed immunotherapy.
• Current strategies face challenges with high relapse rates, indicating a need for novel approaches to achieve long-term remission.